| Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours (NCT03518606) | UNICANCER | 2018-06-20 |
| A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007) (NCT03565068) | Merck Sharp & Dohme LLC | 2018-06-20 |
| This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors) (NCT03449381) | Boehringer Ingelheim | 2018-06-20 |
| Safety and PK/PD of RTA 1701 in Healthy Adults (NCT03579030) | Biogen | 2018-06-20 |
| First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS (NCT03554408) | Rockefeller University | 2018-06-20 |
| Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A (NCT03624959) | Celgene | 2018-06-20 |
| Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging (NCT03470259) | University Medical Center Groningen | 2018-06-20 |
| A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia （SAA） Patient (NCT03557099) | Jiangsu HengRui Medicine Co., Ltd. | 2018-06-20 |
| Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma (NCT03217266) | National Cancer Institute (NCI) | 2018-06-20 |
| Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma (NCT03619239) | Genexine, Inc. | 2018-06-20 |
| CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms (NCT03566446) | Inge Marie Svane | 2018-06-20 |
| Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors (NCT03010982) | Epizyme, Inc. | 2018-06-20 |
| A Study to Assess the Safety and Tolerability of SOBI003 in Pediatric MPS IIIA Patients (NCT03423186) | Swedish Orphan Biovitrum | 2018-06-19 |
| A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma (NCT03294083) | SillaJen, Inc. | 2018-06-19 |
| A Study of LY03005 vs Pristiq (NCT03733574) | Luye Pharma Group Ltd. | 2018-06-19 |
| Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults (NCT03408899) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-06-19 |
| A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis (NCT03423121) | Johns Hopkins University | 2018-06-19 |
| Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies (NCT03407976) | University of Utah | 2018-06-19 |
| Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer (NCT03394885) | Duke University | 2018-06-19 |
| Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma (NCT03502148) | Privo Technologies | 2018-06-19 |
| The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer (NCT03444376) | Genexine, Inc. | 2018-06-19 |
| Effect of Cimetidine on the PK of Imeglimin (NCT03618316) | Poxel SA | 2018-06-19 |
| A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease (NCT03701555) | Millennium Pharmaceuticals, Inc. | 2018-06-19 |
| Study of BAY1834942 in Patients With Solid Tumors (NCT03596372) | Bayer | 2018-06-19 |
| Safety, Tolerability and Pharmacokinetic Profile of an Infusion of Cilastatin in Healthy Volunteers. (NCT03595189) | Spherium Biomed | 2018-06-19 |
| Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) (NCT03527147) | Acerta Pharma BV | 2018-06-19 |
| Bioequivalence of Flurbiprofen Lozenge vs Strepfen (NCT04670601) | Aziende Chimiche Riunite Angelini Francesco S.p.A | 2018-06-19 |
| A Bioequivalence Study of Two Nicotine Lozenges in Fasting Conditions in Healthy Smokers (NCT03541044) | GlaxoSmithKline | 2018-06-18 |
| Praziquantel Bioequivalence Study (NCT03437447) | Merck KGaA, Darmstadt, Germany | 2018-06-18 |
| A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102 (NCT03636477) | Alaunos Therapeutics | 2018-06-18 |
| Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Peritoneal Malignancies (NCT03443674) | Clover Biopharmaceuticals AUS Pty | 2018-06-18 |
| A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies (NCT03538028) | Incyte Biosciences International Sàrl | 2018-06-18 |
| A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese (NCT03574584) | Novo Nordisk A/S | 2018-06-18 |
| A Study to Compare the Relative Bioavailability of Two Different Formulations of GSK3640254 (NCT03575962) | ViiV Healthcare | 2018-06-18 |
| Comparison of Metformin and Pioglitazone in Regulating Menstrual Irregularities and Hyperandrogenism (NCT03757923) | Dow University of Health Sciences | 2018-06-18 |
| To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the Reference Product (Nicorette) in Healthy Smokers (NCT03543137) | GlaxoSmithKline | 2018-06-18 |
| Cold Plasma for Wound Treatment, Safety Study (NCT03007264) | Association of Dutch Burn Centres | 2018-06-18 |
| Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC (NCT03347292) | Bayer | 2018-06-18 |
| Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin (NCT03801733) | Akebia Therapeutics | 2018-06-17 |
| TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects (NCT03675880) | Lee's Pharmaceutical Limited | 2018-06-15 |
| Study of Intracoronary CD34+ Cell Administration in Patients With Early Coronary Atherosclerosis (NCT03471611) | Mayo Clinic | 2018-06-15 |
| A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted (NCT03547245) | International AIDS Vaccine Initiative | 2018-06-15 |
| Supporting the Transition to and Engagement in Parenthood (NCT04829864) | Université du Québec à Trois-Rivières | 2018-06-15 |
| Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers (NCT03515551) | Immunocore Ltd | 2018-06-15 |
| A Study to Evaluate the Effects of NST-4016 on QT/Corrected QT (QTc) Interval (NCT03577275) | NorthSea Therapeutics B.V. | 2018-06-15 |
| Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation (NCT03513328) | University of Florida | 2018-06-15 |
| Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer (NCT03323658) | National Cancer Institute (NCI) | 2018-06-15 |
| PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL (NCT03543813) | CytomX Therapeutics | 2018-06-15 |
| Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma (NCT03425461) | Jonsson Comprehensive Cancer Center | 2018-06-14 |
| Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg (NCT03350295) | Bayer | 2018-06-14 |
| Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma (NCT03558750) | Vanderbilt-Ingram Cancer Center | 2018-06-14 |
| A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors (NCT03516123) | CStone Pharmaceuticals | 2018-06-14 |
| Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma (NCT03031730) | National Cancer Institute (NCI) | 2018-06-14 |
| Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function (NCT03562117) | GlaxoSmithKline | 2018-06-14 |
| Pharmacokinetic Study of Intranasal Dexmedetomidine in Pediatric Patients With Congenital Heart Disease (NCT03417999) | Children's Hospital of Philadelphia | 2018-06-14 |
| Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study (NCT03555617) | Theravance Biopharma | 2018-06-13 |
| Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma (NCT03341806) | Icahn School of Medicine at Mount Sinai | 2018-06-13 |
| First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin (NCT03507452) | Bayer | 2018-06-13 |
| Tepotinib Hepatic Impairment Trial (NCT03546608) | EMD Serono Research & Development Institute, Inc. | 2018-06-13 |
| H5N1 With or Without Topical Aldara in Healthy Adults (NCT03472976) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-06-13 |
| Comparative Study to Evaluate the Pharmacokinetics of BAT1806 vs Actemra® in Healthy Subjects (NCT03606876) | Bio-Thera Solutions | 2018-06-13 |
| Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers (NCT03077477) | Aminex Therapeutics, Inc. | 2018-06-12 |
| A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function (NCT03799848) | Akebia Therapeutics | 2018-06-12 |
| A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients (NCT03502681) | Monika Joshi, MD | 2018-06-12 |
| Autologous Bronchial Basal Cell Transplantation for Treatment of COPD (NCT03188627) | Regend Therapeutics | 2018-06-12 |
| Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma. (NCT03224104) | European Organisation for Research and Treatment of Cancer - EORTC | 2018-06-12 |
| Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects (NCT03594890) | Osivax | 2018-06-12 |
| Evaluating the Pharmacokinetic Interaction Between AD-2011 and AD-2012 (NCT03586037) | Addpharma Inc. | 2018-06-12 |
| Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA) (NCT03510468) | National Institutes of Health Clinical Center (CC) | 2018-06-12 |
| A Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Participants (NCT03564379) | Janssen Research & Development, LLC | 2018-06-12 |
| Oral AMXT 1501 Dicaprate in Combination With DFMO (NCT03536728) | Aminex Therapeutics, Inc. | 2018-06-12 |
| A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers (NCT03567642) | Memorial Sloan Kettering Cancer Center | 2018-06-12 |
| A Study to Compare Pharmacokinetic and Safety of TRS003 to China-approved Bevacizumab and US-licensed Avastin® (NCT03882424) | Zhejiang Teruisi Pharmaceutical Inc. | 2018-06-12 |
| A Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of KMRC011 (NCT03585803) | Intron Biotechnology, Inc. | 2018-06-11 |
| GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study (NCT03751761) | Asan Medical Center | 2018-06-11 |
| Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and Furosemide (NCT07173738) | Bial - Portela C S.A. | 2018-06-11 |
| Bioequivalence Study of Ibuprofen D, Oral Suspension, 200 mg/5ml and Nurofen®, Oral Suspension 100 mg/5 ml in Healthy Volunteers Under Fasting Conditions (NCT03561558) | Pharmtechnology LLC | 2018-06-11 |
| Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers (NCT03536481) | Betta Pharmaceuticals Co., Ltd. | 2018-06-11 |
| APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma (NCT03502330) | Yale University | 2018-06-09 |
| Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma (NCT04067414) | Institute of Hematology & Blood Diseases Hospital, China | 2018-06-08 |
| Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis (NCT03493841) | Rebecca Spain | 2018-06-08 |
| VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (NCT03556228) | VM Oncology, LLC | 2018-06-08 |
| A Study in Healthy Participants to Evaluate the Effects of Multiple Doses of JNJ-55308942 on Cytochrome P450 Substrate Activity and on the Pharmacokinetics of Levonorgestrel/Ethinyl Estradiol (NCT03547024) | Janssen-Cilag International NV | 2018-06-08 |
| Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain (NCT03477487) | Xalud Therapeutics, Inc. | 2018-06-08 |
| A Pharmacokinetic Study of the Effect of Itraconazole Exposure to Orvepitant in Healthy Volunteers (NCT03535662) | Nerre Therapeutics Ltd. | 2018-06-08 |
| Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease (NCT02150551) | Catherine Bollard | 2018-06-07 |
| Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury (NCT03482037) | RECORDATI GROUP | 2018-06-07 |
| Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients (NCT03509584) | Assistance Publique Hopitaux De Marseille | 2018-06-07 |
| A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors (NCT03627741) | Mayo Clinic | 2018-06-07 |
| Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) (NCT03258593) | National Cancer Institute (NCI) | 2018-06-07 |
| A Single Ascending Dose Study of BTZ043 (NCT03590600) | Michael Hoelscher | 2018-06-07 |
| A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia (NCT03627195) | Sumitomo Pharma America, Inc. | 2018-06-07 |
| A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers (NCT03571594) | Ono Pharmaceutical Co., Ltd. | 2018-06-07 |
| A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy Subjects (NCT03561298) | BeiGene | 2018-06-07 |
| Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR®) Treatment With Solid Tumor (NCT03406364) | Metagone Biotech Inc. | 2018-06-06 |
| A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers (NCT03448042) | Genentech, Inc. | 2018-06-06 |
| A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal Function (NCT03546205) | Janssen Research & Development, LLC | 2018-06-06 |
| Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT03498378) | Kathryn Gold | 2018-06-06 |
| A Study to Investigate the Effects of Cortexolone 17α-propionate (and Its Metabolites) on Healthy Volunteers' Heart (NCT03665194) | Cassiopea SpA | 2018-06-06 |
| Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer (NCT03518242) | Fred Hutchinson Cancer Center | 2018-06-06 |